Cogent Biosciences Inc (COGT)

(COGT) Trading Advice - Stock Traders Daily

Stock Traders Daily

Cogent Biosciences, Inc. Expected to Post Q2 2024 Earnings of ($0.60) Per Share (NASDAQ:COGT) - Defense World

Defense World

Investor's Toolkit: Key Ratios for Assessing Cogent Biosciences Inc (COGT)'s Performance – DWinneX - The Dwinnex

The Dwinnex

HC Wainwright Weighs in on Cogent Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:COGT) - MarketBeat

MarketBeat

Take off with Cogent Biosciences Inc (COGT): Get ready for trading – Sete News - SETE News

SETE News

Cogent Biosciences (NASDAQ:COGT) Rating Reiterated by HC Wainwright - Defense World

Defense World

Cogent Biosciences Inc (COGT) stock: A year of ups and downs – US Post News - US Post News

US Post News

Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

MarketBeat

We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth - Yahoo Finance

Yahoo Finance

Cogent Biosciences' (COGT) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Defense World

Cogent Biosciences (COGT) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Fisher Asset Management LLC - Defense World

Defense World

Wedbush Comments on Cogent Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:COGT) - Defense World

Defense World

Q2 2024 Earnings Estimate for Cogent Biosciences, Inc. (NASDAQ:COGT) Issued By Leerink Partnrs - Defense World

Defense World

Cogent Biosciences, Inc. to Post Q2 2024 Earnings of ($0.66) Per Share, Leerink Partnrs Forecasts (NASDAQ:COGT) - MarketBeat

MarketBeat

Zurcher Kantonalbank Zurich Cantonalbank Buys 7606 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Defense World

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $13.67 Consensus PT from Brokerages - MarketBeat

MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Defense World

Cogent Biosciences (NASDAQ:COGT) Issues Quarterly Earnings Results - MarketBeat

MarketBeat

Cogent Biosciences (NASDAQ:COGT) Receives Buy Rating from Needham & Company LLC - MarketBeat

MarketBeat

Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewswire

GlobeNewswire

Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewswire

GlobeNewswire

(COGT) Investment Report - Stock Traders Daily

Stock Traders Daily

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR ... - GlobeNewswire

GlobeNewswire

5 Best Medical Stocks to Buy Under $10 - Insider Monkey

Insider Monkey

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance

Yahoo Finance

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

GlobeNewswire Inc.

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with ... - Yahoo Finance

Yahoo Finance

5 Best Booming Stocks to Buy Right Now - Insider Monkey

Insider Monkey

Cogent Biosciences Launches $225M Private Stock Sale - TipRanks.com - TipRanks

TipRanks

Steven Cohen's Point72 Asset Management Bolsters Position in Cogent Biosciences - Yahoo Finance

Yahoo Finance

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst (COGT) - Seeking Alpha

Seeking Alpha

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

GlobeNewswire Inc.

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and ... - Yahoo Finance

Yahoo Finance

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Analyst Expectations for Cogent Biosciences's Future

Benzinga

Nasdaq Edges Higher; Macy's Shares Jump

Benzinga

Dow Surges 100 Points; Cogent Biosciences Shares Plunge

Benzinga

Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday

Benzinga

US Stocks Mixed; Cigna Shares Spike Higher

Benzinga

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

GlobeNewswire Inc.

ASH 2023: Phase II case Cogent enough with bezu in mastocytosis? Street skeptical, more data soon - BioWorld Online

BioWorld Online

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

GlobeNewswire Inc.

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients ... - GlobeNewswire

GlobeNewswire

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

GlobeNewswire Inc.

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium - GlobeNewswire

GlobeNewswire

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Yahoo Finance

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI ... - GlobeNewswire

GlobeNewswire